GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...

GSK’s share price has fallen a long way on a combination of factors, but do its recent strong results leave its current price looking cheap to me?

Shares of GSK PLC GSK rose 1.79% to £14.47 Thursday, on what proved to be an all-around rough trading session for the stock ...

International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...

Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock ...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might ...

Importantly, our data indicates that GSK's profit was reduced by UK£2.5b, due to unusual items, over the last year. It's ...

The UK's major stock indexes have declined for the third consecutive session, influenced by mixed corporate earnings and ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

UK pharma major GSK late Friday announced that the US Food and Drug Administration (FDA) has approved Penmenvy (meningococcal ...

GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.